In HNSCC, Koole et al. proposed co-administration of Gefitinib in FGFRi-resistant HNSCC cells [20] in contrast to Singleton et al. who preferred ERBB2 instead of EGFR or cMET inhibition [21]. Here, ERBB2 is linked to head and neck squamous cell carcinoma.